WO1995006131A1 - Methode de depistage, de prophylaxie et/ou de traitement de maladies affectant l'homme - Google Patents

Methode de depistage, de prophylaxie et/ou de traitement de maladies affectant l'homme Download PDF

Info

Publication number
WO1995006131A1
WO1995006131A1 PCT/AU1994/000498 AU9400498W WO9506131A1 WO 1995006131 A1 WO1995006131 A1 WO 1995006131A1 AU 9400498 W AU9400498 W AU 9400498W WO 9506131 A1 WO9506131 A1 WO 9506131A1
Authority
WO
WIPO (PCT)
Prior art keywords
vpf
ohss
antagonist
antibody
biological sample
Prior art date
Application number
PCT/AU1994/000498
Other languages
English (en)
Inventor
David Mark Milne-Roberts
Neil Mcclure
David Lindsay Healy
Original Assignee
Monash University
Prince Henry's Institute Of Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Prince Henry's Institute Of Medical Research filed Critical Monash University
Priority to AU74858/94A priority Critical patent/AU7485894A/en
Publication of WO1995006131A1 publication Critical patent/WO1995006131A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates generally to a diagnostic assay for ovarian hyperstimulation syndrome and to a method of preventing or treating same.
  • the present invention also relates to the assay and treatment of tumours and cancers which require enhanced vascular permeability for growth.
  • Ovarian hyperstimulation syndrome (hereinafter referred to as "OHSS") is characterised by the ovaries becoming rapidly enlarged and by increased capillary permeability within the abdominal and to a lesser extent, thoracic cavities. OHSS appears to result from an over stimulation of normal ovarian physiological processes. Although the exact cause of OHSS is apparently unknown, it only develops in women undergoing ovulation induction. The likelihood and severity of OHSS appears to be related to the level of ovarian response to stimulation with fertility drugs such as clomiphene citrate, human chorionic gonadotropin (hCG), human menopausal gonadotropin, follicle stimulating hormone (FSH) and lutienising hormone releasing hormone (LHRH). The syndrome is a potentially life-threatening, major complication of ovarian induction therapy.
  • hCG human chorionic gonadotropin
  • FSH follicle stimulating hormone
  • LHRH lutienising hormone releasing hormone
  • ovulation therapy such as ovarian stimulation in assisted reproduction or in vitro fertilization (IVF)
  • IVF in vitro fertilization
  • these techniques provide indirect evidence for OHSS, they are necessarily subjective and frequently a putative diagnosis occurs too late in the ovulation protocol to take preventative measures.
  • a diagnostic assay for OHSS so that women can be accurately assessed during ovulation therapy.
  • VPF Vascular Permeability Factor
  • VEGF Vascular Endothelial Growth Factor
  • one aspect of the present invention contemplates a method for assaying for a disease condition in a human subject wherein said disease condition results from or is otherwise promoted by enhanced vascular permeability, said method comprising screening for and/or quantitating the presence of VPF over time in a biological sample of said human subject wherein an elevation of VPF in said biological sample relative to a normal control is indicative of or a propensity to develop said disease condition.
  • the present invention relates generally to any human disease condition requiring enhanced vascular permeability for its development or at least its maintenance.
  • diseases conditions include OHSS following ovulation therapy or a variety of tumours or cancers such as ovarian cancer.
  • a particularly important aspect of the present invention is the ability to detect OHSS as soon as possible during ovulation therapy.
  • the detection of OHSS or a propensity to develop OHSS at an early stage may assist the clinician in reducing further development of the condition by, for example, stopping or reducing ovarian stimulation, delaying embryo transfer or initiating a therapeutic protocol to reduce OHSS development.
  • a method for assaying for OHSS in a human subject comprising screening for and/or quantitating the presence of VPF over time in a biological sample of said human subject wherein an elevation of VPF in said biological sample relative to a normal control is indicative of OHSS or a propensity to develop OHSS.
  • an increase in VPF over time is indicative of the development of or at least potential development of OHSS.
  • the results over time are preferably quantitative although the subject method is also adaptable for qualitative analysis.
  • a "normal control” is meant the levels of VPF in a reproductive age female not undergoing ovarian stimulation.
  • An “elevation” is considered to mean a statistically significant increase in the amount of VPF.
  • the biological sample used in accordance with the present invention is any suitable and conveniently obtained fluid containing or potentially containing VPF.
  • the fluid is selected from urine, serum, ovarian follicular fluid, saliva, peritoneal fluid, pleural fluid and pericardial fluid.
  • the fluid is urine or serum.
  • the VPF is measured prior to administration of an ovulating hormone (e.g. hCG lutienizing hormone or recombinant forms thereof) or prior to egg pick up. If elevated levels of VPF cannot be measured prior to administration of ovulating hormone, then preferably VPF is measured within an approximately 48 hour period and more preferably within an approximately 30 hour period following ovarian hormone administration.
  • an ovulating hormone e.g. hCG lutienizing hormone or recombinant forms thereof
  • a method for assessing the development or potential development of OHSS in a human subject undergoing ovarian stimulation in assisted reproduction comprising determining the levels of VPF in a biological sample from said human subject period either before administration of an ovulating hormone or prior to embryo transfer and comparing said levels to a normal control wherein an increase over the normal control is indicative or predictive of the development of OHSS.
  • the assay for VPF is most conveniently conducted using antibodies specific to VPF or to an antibody binding fragment, part, derivative, homologue or analogue thereof. Alternatively, antibodies cross reactive with VPF may also be used with appropriate controls.
  • the antibodies may be monoclonal or polyclonal, monoclonal antibodies are preferred particularly because of the ability to produce them in large quantities and due to the homogeneity of the product.
  • the antibodies may be prepared in the laboratory as described hereinafter. The antibodies used in the experiments ofthe present invention were obtained from Monsanto Company, St. Louis, Missouri, USA.
  • Monoclonal antibodies to VPF and like molecules are prepared from hybridoma cell lines derived by fusing an immortal cell line and lymphocytes sensitised against VPF.
  • Techniques for preparing monoclonal antibodies are well known in the art and reference can conveniently be made to Douillard and Hoffman, "Basic Facts About Hybridomas" in Compendium of Immunology Vol II ed by Schwarts; Kohler and Milstein Nature 256: 495-499, 1975; European Journal of Immunology 6: 511-519, 1976; and in US Patent No. 5,036,003 (Monsanto Company).
  • VPF VPF in a patient's biological fluid
  • immunoassay techniques such as those described in US Patent Nos. 4,016,043, 4,424,279 and 4,018,653. This includes both single-site and two- site, or "sandwich", assays of the non-competitive types, as well as in the traditional competitive binding assays.
  • Sandwich assays are particularly useful and include ELISA dip-stick assays and Immunofluorometric assays (IFA).
  • Competitive binding assays include radioimmunoassays (RIA). Western blot assays may also be used. The choice of assay will depend on the sensitivity required, materials available and the biological sample employed.
  • an unlabelled antibody capable of binding VPF is immobilised onto a solid substrate and the biological sample to be tested for VPF brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to allow formation of an antibody- VPF primary complex, a VPF specific antibody, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of a secondary complex of antibody- VPF-labelled antibody. Any unreacted material is washed away, and the presence of the VPF is determined by observation of a signal produced by the reporter molecule on the second antibody.
  • the results may either be qualitative, by simple observation of the visible signal or may be quantitated by comparing with a control sample containing known amounts of VPF. Variations of this assay include a simultaneous assay, in which both sample and labelled antibody are added simultaneously to the bound antibody, or a reverse assay in which the labelled antibody and sample to be tested are first combined, incubated and then added simultaneously to the bound antibody. Furthermore, the second antibody may be unlabelled and a labelled anti-immunoglobulin antibody used to detect bound second antibody. These techniques are well known to those skilled in the art, and the possibility of minor variations will be readily apparent.
  • the antibodies used above may be monoclonal or polyclonal.
  • a first antibody having specificity for VPF or antigenic parts thereof is either covalently or passively bound to a solid surface.
  • the solid substrate is typically glass or a polymer, the most commonly used polymers being cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
  • the solid supports may be in the form of tubes, beads, discs or microtitre plates, or any other surface suitable for conducting an immunoassay such as a dipstick.
  • the binding processes are well-known in the art and generally consist of cross-linking, covalently binding or physically adsorbing the molecule to the insoluble carrier.
  • reporter molecule a molecule which, by its chemical nature, produces an analytically identifiable signal which allows the detection of VPF-bound antibody.
  • reporter molecules include enzymes, fluorophores and radionuclide containing molecules (i.e. radioisotopes).
  • an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate.
  • Commonly used enzymes include horseradish peroxidase, glucose oxidase, ⁇ -galactosidase and alkaline phosphatase, amongst others.
  • the substrates to be used with the specific enzymes are generally chosen for the production,upon hydrolysis by the corresponding enzyme, of a detectable colour change.
  • fluorescent compounds such as fluorescein, anthanide such as europium and rhodamine
  • fluorescent compounds may be chemically coupled to antibodies without altering their binding capacity.
  • the fluorochrome-labelled antibody When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody adsorbs the light energy, inducing a state of excitability in the molecule, followed by emission of the light at a characteristic colour visually detectable with a light microscope.
  • EIA enzyme immunoassay
  • the fluorescent labelled antibody is allowed to bind to VPF in the first antibody- VPF complex. After washing off the unbound reagent, the remaining ternary complex is then exposed to the light of the appropriate wavelength, the fluorescence observed indicates the presence of the hapten of interest.
  • Immunofluorescence and EIA techniques are both very well established in the art and are particularly preferred for the present method.
  • reporter molecules such as radioisotopes, chemiluminescent molecules or bioluminescent molecules may also be employed. It will be readily apparent to the skilled technician how to vary the procedure to suit the required purpose. It will also be apparent that VPF in a sample could be captured by other than antibodies.
  • one aspect ofthe present invention contemplates a method of detecting VPF in a biological sample, said method comprising the steps of contacting said biological sample with an immobilised antibody to VPF for a time and under conditions sufficient for a VPF-antibody complex to form and subjecting said complex to a detecting means.
  • the latter complex may be detected by, for example, the addition of a second antibody labelled with a reporter molecule and specific for said VPF.
  • a competitive immunoassay may be used.
  • the most convenient assay of this type is a radioimmunoassay (RIA).
  • reagents required generally include an antiserum raised to VPF (e.g. recombinant human VPF), a labelled VPF (e.g. iodinated recombinant human VPF) and VPF as standard (e.g. recombinant human VPF).
  • VPF radioimmunoassay
  • VPF e.g. recombinant human VPF
  • VPF e.g. iodinated recombinant human VPF
  • VPF as standard e.g. recombinant human VPF
  • the standard VPF or biological sample to be tested is incubated with an appropriate dilution of antisera. Incubation may range from minutes or hours to days. Labelled (e.g.
  • VPF iodinated VPF
  • test tubes incubated for a further period ranging from minutes or hours to days.
  • An anti-IgG serum is then added to precipitate the VPF-antibody complex.
  • the levels of VPF in the sample are determined using standard data management systems.
  • the biological samples may be used directly or first concentrated or diluted.
  • urine it is preferable to first remove small molecular weight components by, for example, gel filtration to ensure these components do not interfere with the assay.
  • VPF as a ratio with creatinine.
  • the present invention is also directed to a kit for assaying for VPF in a biological sample.
  • the kit comprises in compartmental form, a first container adapted to receive a biological sample.
  • the first container contains an antibody specific to VPF immobilised to all or a part of its inner surface.
  • the kit also comprises a second container adapted to contain an antibody specific to VPF and labelled with a reporter molecule.
  • the kit may also contain other containers adapted to contain reagents, diluents and/or substrates to facilitate the assay.
  • the kit may comprise a first container adapted to contain a biological sample, a second container adapted to contain VPF and a third container adapted to contain a labelled VPF (e.g. iodinated VPF).
  • a labelled VPF e.g. iodinated VPF
  • OHSS OH-SS-like pharmacological response to OHSS
  • One therapeutic protocol is based on withholding administration of native or recombinant hCG (or other ovulation stimulating compound such as lutienizing hormone) or withholding embryo transfer or modifying other aspects of treatment which may promote OHSS.
  • the protocol may use antagonists of VPF.
  • a method for preventing or ameliorating the effects of OHSS in a female patient undergoing ovulation therapy comprises screening for and/or quantitating the presence of VPF over time in a biological sample of said human subject wherein an elevation of VPF in said biological sample relative to a normal control is indicative of or a propensity to develop OHSS and thereafter modifying the ovulation therapy to prevent development of OHSS.
  • a modification would include: (i) withholding administration of ovulating hormone (e.g. hCG); (ii) withholding embryo transfer; (iii) surgical intervention; and/or
  • a method for preventing or ameliorating the effects of OHSS in a female patient comprising administering to said patient, a VPF inhibiting effective amount of an antagonist to VPF for a time and under conditions sufficient to inhibit, reduce or otherwise ameliorate the effects of the symptoms of OHSS.
  • the present invention also contemplates a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a VPF antagonist and one or more pharmaceutically acceptable carriers and/or diluents.
  • a VPF antagonist Any of a range of VPF antagonists may be used such as antibodies specific to VPF or fragments, parts or peptide components of VPF or receptor antagonists of VPF. All such molecules are encompassed by the term "VPF antagonist".
  • a non-human antibody When a non-human antibody is employed as an antagonist, it may first need to be "humanised” meaning that parts ofthe antibody are substituted with parts of human proteins to reduce or minimise the risk of an immune response against the antibody.
  • the active ingredients of the pharmaceutical composition comprising the VPF antagonist are contemplated to exhibit excellent therapeutic activity, for example, in the prevention or amelioration of OHSS when administered in an amount which depends on the particular case. For example, from about 0.5 ⁇ g to about 20 mg per kilogram of body weight per day may be administered. Dosage procedures may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily, weekly, monthly or in other suitable time intervals or the dose may be proportionally reduced as indicated by the exigencies of the situation.
  • the active compound may be administered in any convenient manner such as by the oral, intravenous (where water soluble), intramuscular, subcutaneous, intranasal, intradermal or suppository routes or implanting (eg using slow release molecules).
  • the active ingredients which comprise one or more antagonists may be required to be coated in a material to protect said ingredients from the action of enzymes, acids and other natural conditions which may inactivate said ingredients.
  • low lipophilicity of the antagonists may allow them to be destroyed in the gastrointestinal tract by enzymes capable of cleaving peptide bonds and in the stomach by acid hydrolysis.
  • the antagonists will be coated by, or administered with, a material to prevent their inactivation.
  • the antagonists may be administered in an adjuvant, co- administered with enzyme inhibitors or in liposomes.
  • Adjuvant is used in its broadest sense and includes any immune stimulating compound such as interferon.
  • Adjuvants contemplated herein include resorcinols, non-ionic surfactants such as polyoxyethylene oleyl ether and n-hexadecyl polyethylene ether.
  • the active compound may also be administered in dispersions prepared in glycerol, liquid polyethylene glycols, and/or mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size ' in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thormerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by, for example, the use in the compositions of agents delaying absorption.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredient(s) into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder ofthe active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • the composition may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.01% by weight and more preferably at least 0.1-1% by weight of active compound.
  • compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% ofthe weight ofthe unit.
  • the amount of active compound in the pharmaceutical compositions is such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.5 ⁇ g and 200 mg and more preferably lO ⁇ g and 20 mg of active compound.
  • the tablets, pills, capsules and the like may also contain the following: a binder such as gum gragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring.
  • a binder such as gum gragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • pharmaceutically acceptable carriers and diluents include any and all solvents, dispersion media, aqueous solutions, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the human subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutc effect in association with the required pharmaceutical carrier and/or diluent.
  • the specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics ofthe active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseases condition in which bodily health is impaired as herein disclosed in detail.
  • VPF VPF
  • tumours and cancers which require for growth enhanced vascular permeability
  • ovarian cancer ovarian cancer
  • the methods of assay, kits, methods of treatment and pharmaceutical compositions herein described therefore, also extend to the detection, monitoring and treatment of these tumours and cancers such as ovarian cancer.
  • reference to "ovarian cancer” includes reference to tumours and cancers requiring for growth enhanced vascular permeability.
  • another aspect ofthe present invention contemplates a method for assaying for ovarian cancer in a human subject, said method comprising monitoring the presence of VPF in a biological sample of said human subject wherein a substantial elevation of VPF in said biological sample relative to a normal control is indicative of ovarian cancer or a propensity to develop ovarian cancer.
  • a normal control is a female without OHSS or ovarian cancer.
  • a further aspect of the instant invention contemplates a method for preventing or ameliorating the effects of ovarian cancer said method comprising administering to said human subject a VPF inhibiting effective amount of an antagonist to VPF for a time and under conditions sufficient to inhibit, reduce or otherwise ameliorate the symptoms of ovarian cancer.
  • VPF can be used as a marker for early stages of ovarian cancer or for recurrence of ovarian cancer. It also provides a marker to correlate with ovarian ultrasound appearances and colour cloppler assessment of ovarian blood flow. The measurement of VPF additionally provides a convenient marker to monitor ovarian cytotoxic chemotherapy and other treatments employed in ovarian cancer such as oophoarectomy. VPF may also be a suitable marker for pre-malignant ovarian diseases.
  • the present invention contemplates the use of a ribozyme to VPF mRNA to reduce levels of VPF in a human subject.
  • a genetic construct comprising a ribozyme having a hybridising region and a catalytic region wherein said hybridising region is capable of hybridising under in vivo conditions to all or a portion of VPF mRNA wherein said catalytic region is capable of cleaving said mRNA.
  • a ribozyme would be useful in the treatment of OHSS and/or ovarian cancer.
  • genetic therapy in the form of antisense molecules capable of targetting VPF mRNA may be ued.
  • the antisense molecule may be a molecule capable of hybridising to the full length VPF mRNA or to a part or portion thereof.
  • the antisense molecules may be from 7 to 200 nucleotides in length or from 10 to 100 nucleotides in length or from 15 to 150 nucleotides in length.
  • Antisense molecules are conveniently designed from knowledge of the VPF cDNA sequence.
  • Still yet a further aspect of the present invention include an agent comprising an antagonist of VPF useful for preventing or ameliorating the effects of OHSS or ovarian cancer and the use of an antagonist of VPF in the manufacture of a medicament for the treatment of OHSS or ovarian cancer.
  • Figure 1 is a schematic diagram of one protocol used for ovarian stimulation in assisted reproduction.
  • Figure 2 is a graphical representation showing chromatographic fractionation of ascites fluid on an ion exchange column. The vasodilatory activity was detected by the Miles assay.
  • Figure 3 is a graphical representation showing the vasodilatory activity (as detected by the Miles assay) in OHSS ascites and liver ascites with recombinant human VPF when preincubated with and without control goat serum and serum from goats immunised with recombinant human VPF.
  • the OHSS ascites and liver ascites with recombinant human VPF were initially fractionated by ion exchange chromatography (Figure 2) and two pools (I and II) prepared for assay.
  • Figure 4 is a graphical representation showing dose response curves of a urine sample and VPF standard in the VPF radioimmunoassay. The data has been logit log dose transformed to linearise the response lines in order to assess for parallelism between sample and standard.
  • Figure 5 is a graphical representation showing validation of VPF assay, (a) The urinary VPF profile of VPF as measured by RIA following fractionation on reverse phase (RP)- high pressure liquid chromatography (HPLC). (b) As for (a) but spiked with human recombinant VPF.
  • Figure 6 is a graphical representation of urinary VPF levels expressed as VPF/creatinine ratios from urine collections over the day from 8 normal women in the reproductive age.
  • Figure 7 is a graphical representation showing the relationship between VPF levels (expressed as VPF/creatinine ratios) in urine collected early morning and the VPF levels in 24 hour urine collections.
  • Figure 8 is a graphical representation of urinary VPF levels in two individual women undergoing IVF (expressed as VPF/creatinine ratios) who do not show OHSS.
  • Figure 9 is a graphical representation of urinary VPF levels in 10 women undergoing IVF (expressed as VPF/creatinine ratios) who do not show OHSS from 10 days before until 20 days after egg pick up. Values at each day represent the mean ⁇ standard error. The division in the graph at 8 days after egg pick up correspond to cycles which were pregnant. Values in parenthesis are numbers of samples/day. The shaded area corresponds to the days -2 to +4 around the day of egg pick up.
  • Figure 10 is a graphical representation showing the urinary VPF levels in 14 women undergoing IVF (expressed as VFP/creatinine ratios) who do not show OHSS and two women who had moderate OHSS between days -2 to +4 around the day of egg pick up.
  • Figure 11 is a graphical representation showing the urinary VPF levels in three women undergoing IVF (expressed as VPF/creatinine ratios) who showed severe signs of OHSS. Paracentesis (draining of ascites fluid) is designated by arrows. These samples were provided by Dr Haning, Brown University, Womens and Infants Hospital Schau, Rhode Island, USA.
  • Figure 12 is a graphical representation showing the urinary VFP levels in women with a) no reproductive complaints, i.e.
  • FIG. 1 is a schematic representation of one protocol used for ovarian stimulation in assisted reproduction.
  • Fertility drugs such as FSH and gonadotrophin releasing hormone (GnRH) agonist are administered prior to hCG injection.
  • Eggs are collected at day 0.
  • Embryo transfer occurs at around day 1 to 4 or more preferably around 1 to 2.5.
  • OHSS becomes clinically evidence after hCG administration.
  • OHSS ascites fluid was collected at therapeutic paracentesis, twice from three patients with severe OHSS and once from three patients with non-malignant chronic liver failure. Liver failure ascites, as an obstructive back-pressure ascites, acted as a control for the OHSS ascites. Three 5ml pools were prepared: one from the OHSS samples and two from the liver failure samples. Recombinant human VPF (52 ⁇ g, Monsanto Company, St Louis, Missouri, USA) was added to one of the liver ascites pools. Ion exchange chromatography was performed (see Figure 2) and the fractions tested for capillary permeability in the Miles assay (see below). The ion exchange chromatographic conditions were as follows.
  • the fractions were gel filtered in 50mM ammonium acetate pH7, lyophilised and dissolved in 20mM phosphate buffer pH7 containing 0.154M NaCl and 1% w/v bovine serum albumin prior to assay for capillary permeability in the Miles assay (Miles, A A & Miles, E M Journal of Physiology 118: 28-257, 1952).
  • Vascular permeability activity was detected in two regions of the ion exchange chromatograph (designated Pool I and II, see Figure 2) ofthe OHSS ascites with little or no detectable activity observed in the liver failure ascites fluid.
  • the addition of recombinant human VPF to the liver ascites fluid resulted in a similar pattern of activity as OHSS ascites. No activity was detected in tubes 1 to 40.
  • control serum suppressed activity by 17% and 0% and 24% and 27% (not significant), respectively.
  • An assay method was developed consisting of a radioimmunoassay utilising a goat antiserum raised to recombinant human VPF (rhVPF, 165 amino acid form), iodinated rhVPF (iodinated by the chloramine T procedure) and rhVPF as standard.
  • the antiserum and rhVPF were provided by Monsanto Company.
  • the assay consisted of the initial incubation of standard or sample with an appropriate dilution of antisera for one day at room temperature. Iodinated rhVPF was added on day 2 and the tubes maintained a further day at room temperature. A goat anti-rabbit IgG serum was added to precipitate the VPF-antisera complex. The levels of VPF in the sample were determined using standard data management systems.
  • Urine samples were either assayed (a) directly or (b) concentrated (10-20 times) by microconcentrators (e.g. Beverly, MA, USA) and assayed directly or (c) gel filtered on columns in a volitile buffer such as ammonium acetate (e.g. PD10 columns, Pharmacia, Uppsala, Sweden) and lyophilised prior to assay.
  • a volitile buffer such as ammonium acetate (e.g. PD10 columns, Pharmacia, Uppsala, Sweden) and lyophilised prior to assay.
  • gel filtration was routinely used in order to ensure that small molecular weight components in urine did not interfere in the assay. Serum was assayed directly.
  • the assay working range was 0.8-6.5ng rhVPF/ml of sample using this assay, VPF was readily detected in serum and urine samples.
  • VPF levels were determined in urine from women during their reproductive life, during pregnancy and after menopause and the results are shown in Table 1. The VPF levels ranged from non-detectable to 0.4 ng/ml with an average of 0.24 ng/ml. Urine from 2 women with moderate OHSS gave values of 2.5 and 2.7 ng/ml, ten times the values found in women without OHSS. With one woman who had a past history of moderate OHSS and was undergoing gonadrotrophin treatment for IVF showed elevated levels of urinary VPF without any clinical manifestations of OHSS indicating that the measurement of urinary VPF may be useful to predict OHSS.
  • VPF concentrations in serum of women collected in a reproduction endocrine clinic and who represent both fertile and infertile women showed a narrow range of values (Table 2).
  • One woman with OHSS who was monitored over a period of time prior to the observed clinical symptoms of OHSS showed a 50% increase over this period.
  • the increase in both serum and urinary VPF in women with OHSS provides a basis for a diagnostic of OHSS.
  • Example 2 shows 65-79% suppression of capillary permeability in the presence of VPF antiserum identify anti-VPF antibodies as effective antagonists to VPF.
  • VPF immunoassay One aspect of the validation of the VPF immunoassay was to assess for parallelism between VPF in a sample and VPF in standards. Levels of VPF over a range of dilutions were determined in two urine samples (S.D. #1 and S.D. #2) and in VPF standards by radioimmunoassay. The data are shown in Figure 4. The data have been linearised by logit log-dose transformation. These results affirm the validity of the VPF levels determined in biological samples in the other Examples.
  • the VPF assay was further validated by determining the VPF profile in urine by radioimmunoassay by fractionation on RP-HPLC followed by fractionation of an aliquot of the same urine sample which had been spiked with human recombinant VPF as control. Concentrated urine was divided into two fractions, to one fraction recombinant human VPF was added. These two preparations were fractionated by RP-HPLC on a Aquapore Butyl 10 micron 100 x 100 mm column (Brownlee, San Jose, CA, USA) with 0-50% v/v acetonitrile gradient in 0.1% v/v trifluoracetic acid at 1 ml min and 1 ml/fraction.
  • Urinary VPF was determined as VPF/creatinine ratios from urine collections over the day from 8 normal women of reproductive age. The levels are depicted in Figure 6 and show that there is no variation in urinary VPF throughout the day.
  • Figure 7 shows the relationship between urinary VPF levels (expressed as VPF/creatinine ratios) collected early morning and VPF levels in 24 hour urine collections. The significant correlation indicates that VPF/creatinine ratios of early morning urine collections provides a good index of daily secretion of VPF and, thus, is a reasonable means of monitoring daily urinary VPF excretion.
  • the urinary VPF levels in 10 women undergoing IVF (expressed as VPF/creatinine ratios) who do not show OHSS from 10 days before until 20 days after egg pick up are shown in Figure 8.
  • the clinical protocol is as described in Example 1. Values at each day represent the mean ⁇ standard error.
  • the division in the graph at day 8 after egg pick up corresponds to cycles which were pregnant and not pregnant. The division was made at this day as it is believed that this is the earliest time that the implanted embryo will exert an effect on the uterus. Values in parenthesis are numbers of samples/day.
  • the shaded area corresponds to the days -2 to +4 around the day of egg pick up and is examined in more detail and with more subjects in Example 11.
  • Figure 11 shows the urinary VFP levels in women with a) no reproductive complaints, i.e. normal postmenopausal women, normal women in the reproductive age (see Example 9) women in the reproductive age undergoing IVF (average subject VPF/creatinine values from Example 11) and therefore are considered as controls, (b) benign ovarian tumours, (c) borderline mucinous carcinomas and (d) malignant tumours.
  • the borderline mucinous carcinomas represent a premalignant condition and possibly represents more the benign type of tumour.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte généralement à un dépistage diagnostic ainsi qu'à une méthode de traitement de maladies qui affectent l'homme et sont entretenues ou stimulées par une perméabilité vasculaire accrue. L'invention concerne particulièrement un dépistage du syndrome d'hyperstimulation ovarienne ainsi que la méthode de prévention ou de traitement dudit syndrome. L'invention est fondée en partie sur la corrélation entre des taux élevés du facteur de perméabilité vasculaire et un certain nombre de maladies de l'homme telles que le syndrome d'hypertension ovarienne, les tumeurs et les cancers.
PCT/AU1994/000498 1993-08-23 1994-08-23 Methode de depistage, de prophylaxie et/ou de traitement de maladies affectant l'homme WO1995006131A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU74858/94A AU7485894A (en) 1993-08-23 1994-08-23 A method for the assay, prophylaxis and/or treatment of human disease conditions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPM0765 1993-08-23
AUPM076593 1993-08-23

Publications (1)

Publication Number Publication Date
WO1995006131A1 true WO1995006131A1 (fr) 1995-03-02

Family

ID=3777146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1994/000498 WO1995006131A1 (fr) 1993-08-23 1994-08-23 Methode de depistage, de prophylaxie et/ou de traitement de maladies affectant l'homme

Country Status (1)

Country Link
WO (1) WO1995006131A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111883258A (zh) * 2020-04-30 2020-11-03 浙江大学山东工业技术研究院 一种构建ohss分度分型预测模型的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002058A1 (fr) * 1989-07-27 1991-02-21 California Biotechnology Inc. Production de facteur de croissance de cellules endotheliales vasculaires
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
AU2874292A (en) * 1991-10-24 1993-05-21 Beth Israel Hospital Association, The Assay for malignant effusions
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
WO1994010202A1 (fr) * 1992-10-28 1994-05-11 Genentech, Inc. Antagonistes du facteur de croissance des cellules endotheliales vasculaires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991002058A1 (fr) * 1989-07-27 1991-02-21 California Biotechnology Inc. Production de facteur de croissance de cellules endotheliales vasculaires
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
AU2874292A (en) * 1991-10-24 1993-05-21 Beth Israel Hospital Association, The Assay for malignant effusions
WO1994010202A1 (fr) * 1992-10-28 1994-05-11 Genentech, Inc. Antagonistes du facteur de croissance des cellules endotheliales vasculaires

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ENDOCRINE REVIEWS, (1992), Vol. 13, No. 1, N. FERRARA et al., "Molecular and Biological Properties of the Vascular Endothelial Growth Factor Family of Proteins", pages 18-32. *
ENDOCRINOLOGY, (1990), Vol. 127, No. 2, H.S. PHILLIPS et al., "Vascular Endothelial Growth Factor is Expressed in Rat Corpus Luteum", pages 965-967. *
ENDOCRINOLOGY, Vol. 133, No. 2, K. CULLINAN-BOVE & R.D. KOOS, "Vascular Endothelial Growth Factor/Vascular Permeability Factor Expression in the Rat Uterus: Rapid Stimulation by Estrogen Correlates With Estrogen-induced Increases in Uterine Capillary Permeability and Growth", pages 829-1325. *
JOURNAL OF REPRODUCTION AND FERTILITY, (1993), Vol. 99, A.M. SHARKEY et al., "Expression of mRNA for Vascular Endothelial Growth Factor in Human Placenta", pages 609-615. *
THE JOURNAL OF CLINICAL INVESTIGATION, (1993), Vol. 91, No. 5, "Patterns of Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Mice Suggest a Role in Hormonally Regulated Angiogenesis", pages 2235-2243. *
TRENDS IN CARDIOVASCULAR MEDICINE, (1993), Vol. 3, No. 6, N. FERRARA, "Vascular Endothelial Growth Factor", pages 244-250. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111883258A (zh) * 2020-04-30 2020-11-03 浙江大学山东工业技术研究院 一种构建ohss分度分型预测模型的方法
CN111883258B (zh) * 2020-04-30 2024-03-15 浙江大学山东工业技术研究院 一种构建ohss分度分型预测模型的方法

Similar Documents

Publication Publication Date Title
McAdam Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation
JP2878455B2 (ja) 哺乳類の結合組織マトリックスの分解の指標としてのｙｋｌ−４０の検定方法
Emancipator et al. Experimental IgA nephropathy induced by oral immunization.
Kageshita et al. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma
Hudson et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development
JP4457191B2 (ja) 子癇前症および糖尿病の診断および処置に関する材料および方法
US5310653A (en) Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
Eddie et al. Radioimmunoassay of relaxin in pregnancy with an analogue of human relaxin
JP3943575B2 (ja) 切迫分娩についての危険にある女性における膜の破裂を決定するための検定方法
JP2001505658A (ja) 糖尿病及び肥満症の診断及び治療に関する物質及び方法
PL177771B1 (pl) Linie komórek hybrydoma i preparaty przeciwciał
Takahasi et al. Circulating antibodies against human colonic extract enriched with a 40 kDa protein in patients with ulcerative colitis.
US8399202B2 (en) Peptides for development of diagnostic and therapeutic agents and methods of using same
US20220106369A1 (en) Immunogenic fragment peptide of en2 protein or antibody composition specifically recognizing same
WO1995006131A1 (fr) Methode de depistage, de prophylaxie et/ou de traitement de maladies affectant l'homme
US5766856A (en) Diagnostic method for evaluating advanced glycosylation endproducts using MAC-2 receptor
JP4414023B2 (ja) 関節炎関連メラノトランスフェリンの測定方法および試薬
WO1993024836A1 (fr) Methode de depistage de femmes presentant un risque eleve d'accouchement avant terme
Din et al. Proceedings: Death after partial gastrectomy for peptic ulcer--a long-term study.
EP0757251B1 (fr) Evaluation du changement de la densité minérale d'os et diagnose d'ostéoporose
JP3542227B2 (ja) 免疫試薬
Ito et al. Neurotensin and substance P and dumping syndrome
TANI et al. Serum pepsinogen levels in normal and experimental peptic ulcer rats measured by radioimmunoassay
LEW et al. Alteration of follicle regulatory protein levels in human reproductive disorders: Anovulation
Hengels et al. Evidence for the secretion of gastrin into human gastric juice.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KP KR KZ LK LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA